Search Results - "Lebwohl D"

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors: Motzer RJ Escudier B Oudard S et al.

Source: Lancet. 8/9/2008, Vol. 372 Issue 9637, p449-456. 8p.

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).

Authors: Wilson, P M Yang, D Azuma, M et al.

Source: Pharmacogenomics Journal. Oct2013, Vol. 13 Issue 5, p410-416. 7p.

Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma.

Authors: Korhonen, P. Zuber, E. Branson, M. et al.

Source: Journal of Biopharmaceutical Statistics. Nov/Dec2012, Vol. 22 Issue 6, p1258-1271. 14p. 1 Diagram, 1 Chart, 4 Graphs.

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.

Authors: Grimminger, P P Shi, M Barrett, C et al.

Source: Pharmacogenomics Journal. Oct2012, Vol. 12 Issue 5, p404-411. 8p.

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

Authors: Giatromanolaki, A Koukourakis, M I Sivridis, E et al.

Source: British Journal of Cancer. 9/25/2012, Vol. 107 Issue 7, p1044-1050. 7p. 1 Color Photograph, 2 Charts, 2 Graphs.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors: Baselga J Campone M Piccart M et al.

Source: New England Journal of Medicine. 2/9/2012, Vol. 366 Issue 6, p520-529. 10p.

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer.

Authors: Sternberg, C. N. Whelan, P. Hetherington, J. et al.

Source: Oncology. 2005, Vol. 68 Issue 1, p2-9. 8p. 2 Charts, 6 Graphs.

Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19.

Authors: Reyno, L. Seymour, L. Tu, D. et al.

Source: Women's Oncology Review. Jun2004, Vol. 4 Issue 2, p133-134. 2p.

97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES)

Authors: Calvo, E. Porta, C. Escudier, B. et al.

Source: European Urology Supplements. Apr2010, Vol. 9 Issue 2, p63-64. 2p.

Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema.

Authors: Cohn DM Gurugama P Longhurst HJ et al.

Corporate Authors: Cohn DM Gurugama P Longhurst HJ et al.

Source: The New England journal of medicine [N Engl J Med] 2026 Jun 13. Date of Electronic Publication: 2026 Jun 13.

Publication Type: Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.

Authors: Gillmore JD Gane E Täubel J et al.

Source: The New England journal of medicine [N Engl J Med] 2025 Oct 09; Vol. 393 (14), pp. 1375-1386. Date of Electronic Publication: 2025 Sep 25.

Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

CRISPR-Based Therapy for Hereditary Angioedema.

Authors: Cohn DM Gurugama P Magerl M et al.

Source: The New England journal of medicine [N Engl J Med] 2025 Jan 30; Vol. 392 (5), pp. 458-467. Date of Electronic Publication: 2024 Oct 24.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.

Authors: Fontana M Solomon SD Kachadourian J et al.

Source: The New England journal of medicine [N Engl J Med] 2024 Dec 12; Vol. 391 (23), pp. 2231-2241. Date of Electronic Publication: 2024 Nov 16.

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.

Authors: Longhurst HJ Lindsay K Petersen RS et al.

Source: The New England journal of medicine [N Engl J Med] 2024 Feb 01; Vol. 390 (5), pp. 432-441.

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.

Authors: Ittershagen S Ericson S Eldjerou L et al.

Source: Current hematologic malignancy reports [Curr Hematol Malig Rep] 2019 Feb; Vol. 14 (1), pp. 47-55.

Publication Type: Journal Article; Review

Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 101262565 Publication Model: Print Cited Medium: Internet ISSN: 1558-822X (Electronic) Linking ISSN: 15588211 NLM ISO Abbreviation: Curr Hematol Malig Rep Subsets: MEDLINE

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.

Authors: Gillmore JD Maitland ML Lebwohl D

Source: The New England journal of medicine [N Engl J Med] 2021 Oct 28; Vol. 385 (18), pp. 1722-1723.

Publication Type: Letter; Comment

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors: Yardley DA Noguchi S Pritchard KI et al.

Source: Advances in therapy [Adv Ther] 2013 Oct; Vol. 30 (10), pp. 870-84. Date of Electronic Publication: 2013 Oct 25.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.

Authors: Lebwohl D Anak O Sahmoud T et al.

Source: Annals of the New York Academy of Sciences [Ann N Y Acad Sci] 2013 Jul; Vol. 1291, pp. 14-32. Date of Electronic Publication: 2013 May 09.

Publication Type: Journal Article; Review

Journal Info: Publisher: New York Academy of Sciences Country of Publication: United States NLM ID: 7506858 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1749-6632 (Electronic) Linking ISSN: 00778923 NLM ISO Abbreviation: Ann N Y Acad Sci Subsets: MEDLINE

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

Authors: Gnant M Baselga J Rugo HS et al.

Source: Journal of the National Cancer Institute [J Natl Cancer Inst] 2013 May 01; Vol. 105 (9), pp. 654-63. Date of Electronic Publication: 2013 Feb 19.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 7503089 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2105 (Electronic) Linking ISSN: 00278874 NLM ISO Abbreviation: J Natl Cancer Inst Subsets: MEDLINE

Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.

Authors: Degtyarev E Zhang Y Sen K et al.

Source: JCO precision oncology [JCO Precis Oncol] 2019 Dec; Vol. 3, pp. 1-10.

Publication Type: Journal Article; Review

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE; PubMed not MEDLINE